NASDAQ:ARCT - Arcturus Therapeutics Ltd.
$5.13
 $0.18
+3.67%
1:45PM EDT
2019-02-15
Arcturus Therapeutics Ltd, formerly Alcobra Ltd, incorporated on February 7, 2008, is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ARCT     avg for
industry  
  avg for
sector  
42 stocks weight:  19. 37   0. 00   0. 00  
42 stocks rank:  3. 67 K 1. 86 K 1. 09 K
# analyst opinions:  4. 00   14. 92   14. 43  

quick ratio:  2. 50   5. 37   1. 81  
current ratio:  2. 53   5. 69   2. 19  

target price low:  5. 73   88. 97   117. 82  
target price avg:  6. 84   115. 19   141. 96  
target price high:  7. 32   143. 40   163. 16  
1-yr high:  9. 80   124. 30   142. 77  
last close:  4. 90   101. 85   127. 84  
50-day avg:  5. 07   98. 27   122. 46  
200-day avg:  6. 85   99. 72   122. 70  
1-yr low:  4. 11   78. 19   100. 16  
volume:  6. 71 K 2. 38 M 4. 64 M
50-day avg volume:  23. 33 K 3. 31 M 4. 94 M
200-day avg volume:  26. 96 K 3. 23 M 4. 28 M

1-day return:  -1. 80 % 0. 22 % 0. 48 %
this week return:  -3. 54 % 1. 77 % 2. 01 %
12-wk return:  -21. 85 % 6. 56 % 3. 33 %
52-wk return:  -11. 68 % -2. 23 % 14. 35 %

enterprise value (EV):  20. 65 M 55. 17 B 104. 51 B
market cap:  51. 17 M 49. 01 B 96. 46 B
EBITDA:  -25. 54 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -0. 81   -91. 79   2. 29  
enterprise/revenue (EV/R):  2. 03   29. 84   23. 39  
total revenue:  10. 20 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -26. 05 M 2. 37 B 3. 58 B

shares outstanding:  10. 68 M 607. 99 M 1. 22 B
shares:  6. 54 M 605. 53 M 1. 15 B
shares short:  79. 64 K 11. 62 M 12. 55 M
shares short prior month:  107. 28 K 11. 95 M 13. 44 M
short ratio:  3. 95   4. 82   3. 10  
short % of float:  1. 07 % 6. 19 % 2. 82 %
total cash/share:  3. 06   12. 02   11. 46  
total cash:  32. 83 M 7. 41 B 7. 37 B
operating cash flow:  -10. 00 M 164. 74 M 3. 04 B

book value:  1. 32   14. 43   28. 26  
price/book:  3. 71   -1. 57   -2. 97  
gross profits:  -2. 92 M 8. 28 B 18. 09 B
operating margins:  -255. 66 % -458. 01 % -642. 83 %
EBITDA margins:  -250. 52 % 13. 81 % 22. 47 %
profit margins:  -255. 53 % 6. 57 % 9. 92 %
gross margins:  -61. 71 % 49. 33 % 54. 53 %

1-yr max volatility:  -17. 64 % --- ---
1-yr mean volatility:  0. 06 % 0. 01 % 0. 06 %

1-yr EPS:  -2. 87   3. 03   4. 09  
forward EPS:  -2. 08   4. 33   6. 99  
P/E:  -1. 71   6. 11   26. 91  
forward P/E:  -2. 44   8. 38   10. 48  
PE/G:  -0. 44   0. 37   5. 61  
growth:  3. 90 % 683. 72 % 104. 79 %
earnings high:  -0. 00   1. 27   1. 66  
earnings avg:  -0. 00   1. 01   1. 53  
earnings low:  -0. 00   0. 76   1. 40  
revenue high:  3. 42 M 2. 86 B 11. 19 B
revenue avg:  3. 42 M 2. 78 B 10. 84 B
revenue low:  3. 40 M 2. 67 B 10. 64 B
revenue growth:  3. 90 % 648. 36 % 97. 70 %
revenue/share:  1. 12   14. 68   59. 83  

beta (1yr vs S&P500):  0. 72   1. 21   0. 93  
sharpe (1yr):  0. 24   0. 06   0. 98  

held % insiders:  47. 17 % 6. 46 % 3. 21 %
held % institutions:  15. 05 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ARCT
.        + 0 =             0 :: INITIAL WEIGHT
.  + 305.117 =       305.117 :: inverse volume-to-price addition
.  + 328.161 =       633.278 :: spline projection addition
.  - 151.178 =         482.1 :: poor performance penalty
.    x 0.953 =       459.613 :: one-year gains+dividend factor
.    x 3.913 =       1798.32 :: 13 weeks' performance factor
.    x 1.492 =      2683.973 :: industry recommendation factor
.    x 1.068 =      2866.227 :: EV/R factor
.    x 2.197 =      6297.514 :: revenue growth factor
.    x 2.444 =     15392.294 :: current ratio factor
.    x 1.292 =     19879.329 :: quick ratio factor
.    x 1.119 =     22253.882 :: short ratio factor
.    x 2.037 =     45333.855 :: price-to-book factor
.    x 2.166 =     98211.638 :: P/E weight
.    x 1.229 =    120697.738 :: PE/G factor
.    x 1.598 =    192845.437 :: beta factor
.    x 0.236 =     45594.129 :: sharpe factor
.    x 1.422 =     64836.972 :: target low factor
.     x 1.21 =     78448.719 :: target mean factor
.     x 1.07 =     83963.098 :: target high factor
.    x 1.066 =     89472.152 :: industry 12-weeks return
.    x 0.998 =     89277.046 :: overall "drift" factor
.    x 0.999 =     89208.283 :: largest single-day jump factor
.    x 0.081 =      7264.518 :: low price factor
.      x 1.0 =      7265.006 :: factor hist industry gain for week 06
.   cubeRoot =        19.368 :: reduced for readability
.                     19.368 :: FINAL WEIGHT for NASDAQ:ARCT


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org